摘要
目的观察孟鲁司特、氨溴特罗口服液改善小儿肺炎支原体感染所致呼吸道症状的疗效。方法收集确诊为肺炎支原体感染的下呼吸道感染的患儿147例，简单随机化法分为A、B、C三组，三组均给于常规抗支原体感染及对症治疗，A组44例作为对照组，B组47例给予孟鲁司特，C组56例给予孟鲁司特和氨溴特罗口服液，观察患儿咳嗽、喘息症状缓解情况。结果治疗7d后，三组总有效率：A组79．5％，B组95．7％，C组96．4％。B、C组与A组总有效率差异有统计学意义（X2=5．61、9。54，均P〈0．05）；B、C组问症状完全缓解例数差异也有统计学意义（x2=5．39，P〈0．05），但总有效率差异无统计学意义（x2=0．83，P〉0．05）。结论孟鲁司特及氨溴特罗口服液可以有效改善肺炎支原体感染所致呼吸道感染症状。
Objective To observe the effect of montelukast sodium and ambroxol oral solution in treatment respiratory symptoms caused by mycoplasma infection in children. Methods 147 children who were infected by my- coplasma pneumonia with lower respiratory tracts symptom were randomly divided into A, B, C three groups： group A was control group,group B was treated by montelukast sodium, and group C was treated by montelukast sodium and ambroxol oral solution. Coughing, symptomatic relief of pant were observed in each group. Results After 7 days treat- ment,the total effective rate of three groups was A group 79.5% ,B group 95.7% ,C group 96.4%. Compared with group A,the coughing and panting time in group B and group C were significantly shorter（ X2 = 5.61,9.54, all P 〈 0. 05）, The rate of coughing and panting complete remission in group C was higher compared with group B （ X2 = 5.39,P 〈 0.05）, but there was no statistificantly significant difference in the total efficency between the two groups. Conclusion Montelukast sodium and ambroxol oral solution can effectively improve the symptoms of respiratory tract infection caused by mycoplasma pneumoniae.
出处
《中国基层医药》
CAS
2013年第14期2095-2096,共2页
Chinese Journal of Primary Medicine and Pharmacy
关键词
支原体
肺
呼吸道疾病
孟鲁司特
氨溴特罗
Mycoplasma pulmonis
Respiratory tract diseases
Montelukast
Ambroxol hydrochloride
Clen- buterol hydrochloride
